iScience
January 16, 2026
Amir Valizadeh, John D Roache, Xinyu Zhang et al.
2 citations
Post-traumatic stress disorder (PTSD) exhibits extensive clinical and biological variability, making treatment challenging. The Consortium to Alleviate PTSD (CAP)-ketamine trial, the largest randomized study of ketamine for PTSD, found no overall benefit of ketamine over placebo, underscoring the necessity to identify responsive subgroups. Using pre-treatment blood DNA methylation profiles and...
bioRxiv : the preprint server for biology
August 22, 2025
Jose A Cortes-Briones, Juan Urrutia-Gandolfo, Pablo A Estevez et al.
preprint
The balance between excitatory and inhibitory (E/I) activity is critical for brain function, and its disruption is implicated in neuropsychiatric disorders. Electrophysiological signals can be decomposed into periodic (oscillatory) and aperiodic components. In the power spectrum, the periodic component appears as narrowband peaks, while the aperiodic component underlies its characteristic 1 / f...
Cell Reports Medicine
August 1, 2021
John H. Krystal, Benjamin Kelmendi, Ismene L. Petrakis
13 citations
A promising new Phase III study of MDMA plus psychotherapy for PTSD treatment by Mitchell and colleagues that appeared in Nature Medicine raises important new questions about the biology and optimal treatment of this disorder. A promising new Phase III study of MDMA plus psychotherapy for PTSD treatment by Mitchell and colleagues that appeared in Nature Medicine raises important new questions...
JAMA Psychiatry
March 1, 2019
Gihyun Yoon, Ismene L. Petrakis, John H. Krystal
152 citations
This study examines whether naltrexone pretreatment interferes with the antidepressant effects of ketamine.
Journal of Psychiatric Research
December 24, 2014
Ke Xu, John H. Krystal, Y. Ning et al.
65 citations
Objective Studies of the effects of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, have suggested similarities to the symptoms of schizophrenia. Our primary goal was to evaluate the dimensions of the Positive and Negative Syndrome Scale (PANSS) in ketamine users (acute and chronic) compared to schizophrenia patients (early and chronic stages). Method We conducted...
Journal of Psychopharmacology
February 1, 2010
D. Dickerson, B. Pittman, E. Ralevski et al.
The γ-aminobutyric acid-A (GABA A ) and N-methyl-D-aspartate (NMDA) receptors mediate aspects of the behavioural effects of alcohol. Prior studies reported drugs that block NMDA receptors or facilitate GABA A receptor function produce ethanol-like effects in humans. The purpose of this study was to compare the ethanol-related effects of two pharmacological agents with known NMDA and GABA A...
American Journal of Psychiatry
October 1, 2004
Ismene L. Petrakis, Diana Limoncelli, Ralitza Gueorguieva et al.
143 citations
OBJECTIVE: A family history of alcoholism is a risk factor for the development of ethanol dependence. Ethanol is an antagonist of the N-methyl-d-aspartate (NMDA) glutamate receptor, and alterations in NMDA receptor function are thought to be involved in ethanol abuse and dependence. The purpose of this study was to determine in healthy individuals with no ethanol dependence whether response to...